In this study, we demonstrated, for what we believe to be the first time, that POLQ is a promising therapeutic target in HR-deficient pancreatic cancer using short hairpin RNA-mediated (shRNA-mediated) downregulation in both human and murine models of HR-deficient PDAC. This evidence concerns the gene POLQ and pancreatic neoplasm.